Abstract

- UW's CFRTC PILOT AND FEASIBILITY PROGRAM The objective of the Pilot and Feasibility (P&F) program is to serve the University of Washington's Cystic Fibrosis Research Translation Center's (CFRTC) mission of advancing cystic fibrosis (CF) research to improve the health of people with CF. The P&F program will contribute to this mission by recruiting young scientists, established investigators who have not previously worked in CF, and accomplished CF researchers who are pursuing novel and high risk ideas that represent a clear departure from their established work.
Aim 1. To recruit outstanding early stage and established investigators to CF research in NIDDK interest areas. We will engage promising investigators via personal outreach; interactions with academic and research leaders; and our CF-focused seminars, research meetings, and annual retreat.
Aim 2. To manage the P&F program to maximize the scientific and programmatic impact of funded projects. We will organize rigorous scientific review for pilot study proposals that include multiple internal and external experts and uses the NIH scoring system. Funding will be based on scientific merit, the project's relationship to the CFRTC mission, links to the Cores, and projects' integration with the collaborative groups of NIDDK-focused researchers our center has developed. We will oversee the scientific progress, productivity, and finances of P&F projects.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK089507-11
Application #
9982663
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2010-08-07
Project End
2025-05-31
Budget Start
2020-08-15
Budget End
2021-05-31
Support Year
11
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105

  Publications

Hobler, Mara R; Engelberg, Ruth A; Curtis, J Randall et al. (2018) Exploring Opportunities for Primary Outpatient Palliative Care for Adults with Cystic Fibrosis: A Mixed-Methods Study of Patients' Needs. J Palliat Med 21:513-521
Hull, Rebecca L; Gibson, Ronald L; McNamara, Sharon et al. (2018) Islet Interleukin-1? Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to ?-Cell Failure. Diabetes Care 41:823-830
Heltshe, S L; Khan, U; Beckett, V et al. (2018) Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis. J Cyst Fibros 17:341-347
Irons, Jessica; Hodge-Hanson, Kelsey M; Downs, Diana M (2018) PA5339, a RidA Homolog, Is Required for Full Growth in Pseudomonas aeruginosa. J Bacteriol 200:
Klose, Alexander D; Paragas, Neal (2018) Automated quantification of bioluminescence images. Nat Commun 9:4262
Roch, Melanie; Varela, Maria Celeste; Taglialegna, Agustina et al. (2018) Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients. Antimicrob Agents Chemother 62:
Quon, Bradley S; Sykes, Jenna; Stanojevic, Sanja et al. (2018) Clinical characteristics of cystic fibrosis patients prior to lung transplantation: An international comparison between Canada and the United States. Clin Transplant 32:e13188
West, Natalie E; Goss, Christopher H; Nichols, David P (2018) The Long and the Short of It in Cystic Fibrosis Clinical Research Outcomes. Ann Am Thorac Soc 15:430-431
Kopp, B T; Joseloff, E; Goetz, D et al. (2018) Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosis. J Cyst Fibros :
Bricio-Moreno, Laura; Sheridan, Victoria H; Goodhead, Ian et al. (2018) Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa. Nat Commun 9:2635

Showing the most recent 10 out of 222 publications